VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee ...

If you experience severe or sudden calf pain or suddenly have trouble moving or walking, it’s time to contact a healthcare ...

The unique feline dermatological cases veterinary professionals can see at the clinic, plus how to approach them ...

For the quarter ended September 30, 2024, the Company had a loss from operations of $2.3 million, a 26% year-over-year improvement from $3.1 million for the comparable period of 2023, and a 9% ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $476 from $473 and keeps an Equal ...

The U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance to a standalone lateral lumbar interbody fusion device from the internationally renowned surgeon Randal Betz, M.D.’s company, ...

Theradaptive, a privately held, clinical stage biologics company developing targeted protein therapeutics for spine, orthopedics, soft tissue repair and targeted immuno-oncology, today announced the ...

We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...